VivoSeq
Other

First-Line Treatment

0

Pipeline Programs↗

72

Active Trials↗

18

Companies Involved↗

First-line Treatment is an early-stage landscape with 0 programs across 18 companies. The most active players are Shanghai Henlius Biotech, IO Biotech, Summit Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

32/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

0 programs

PreclinicalI

IO Biotech

0 programs

PreclinicalS

Summit Therapeutics

0 programs

PreclinicalInnovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

0 programs

PreclinicalSuzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

0 programs

PreclinicalC

Chipscreen Biosciences, Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

166

clinical trials

Unknown status60 · 36%
Recruiting41 · 25%
Completed28 · 17%
Not yet recruiting27 · 16%
Active, not recruiting4 · 2%
Terminated3 · 2%
Other3 · 2%

Clinical Trials

Trial Activity

166 trials

Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
Recruiting·TThe First Affiliated Hospital of Nanchang University·N/A·NCT06751940·10 enrolled
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Recruiting·PPeking University Cancer Hospital & Institute·Phase 1·NCT06969612·21 enrolled
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT07122024·414 enrolled
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07117435·7 enrolled
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Recruiting·TThe First Affiliated Hospital of Nanchang University·N/A·NCT06752044·10 enrolled
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06956001·300 enrolled
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Recruiting·SSummit Therapeutics·Phase 3·NCT05899608·1,600 enrolled
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
Recruiting·FFujian Cancer Hospital·Phase 3·NCT07467330·258 enrolled
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Recruiting·SSummit Therapeutics·Phase 3·NCT06767514·780 enrolled
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Recruiting·FFudan University·Phase 3·NCT05760378·223 enrolled
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06360042·111 enrolled
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Recruiting·SSun Yat-sen University·Phase 3·NCT05854849·244 enrolled
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
Recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT05877573·53 enrolled
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Recruiting·TThe First Affiliated Hospital of Nanchang University·N/A·NCT06752057·10 enrolled
Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)